WCN26-1934 Efficacy and safety of telitacicept in treatment of Advanced IgA nephropathy

Read full text Summarise with VIRAT
Authors: Mengjiao Lin, Yanni Zhou, Liangxiang Xiao
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Telitacicept is a recombinant fusion protein that combines the B lymphocyte stimulator (BLyS) receptor with an antibody, effectively inhibiting the abnormal activation of B cells and plasma cells. This mechanism significantly reduces the production of galactose-deficient IgA1 (Gd-IgA1) and subsequently decreases the deposition of immune complexes in the kidneys of IgA nephropathy (IgAN) patients. This study aims to evaluate the efficacy and safety of telitacicept in the treatment of advanced IgAN patients with CKD stage 4.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104299–104299
Publication date
25 March 2026
Language
EN